Stelis Biopharma signs research collaboration agreement with Bio-Scaffold International

Strides Arcolab today announced that its biotech subsidiary, Stelis Biopharma (previously known as Agila Biotech) has entered into a research collaboration agreement with Bio-Scaffold International (BSI), a Singapore-based start-up company.

This collaboration is expected to research and develop BMP and stem cell loaded 3D printed devices for various applications in orthopaedics, cosmetology or plastic and reconstructive surgery and dentistry.

The company said that the research will be jointly directed by Dr Anand Iyer, CEO, Stelis Biopharma and Dr Margam Chandrasekaran, CEO & chief scientist, Bio-scaffold International.

It is said that each company will bear the cost of its contribution to this joint research collaboration.

BSI is a pioneer in the application of 3D printing technology for the development of novel, biocompatible scaffolds.

Stelis is a biotechnology company whose research and development efforts include the development of drug and stem cell loaded devices for the treatment of various medical conditions.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X